Dennis Charney, MD: The Hope of Ketamine for Depression
One of the pioneer investigators of ketamine for depression explains what its recent approval for a severe form of the condition means for patients running out of options.
Read More
Reaching a Future of Optimized Food Allergy Therapies
The first generation of food allergy treatments is nearing the market. What could be next is more individualized therapies.
James Q. Del Rosso, DO: Unlocking Isotretinoin's Benefits
The nodular acne therapy has been a staple treatment for 3 decades, yet new AAD data showed it could still be better utilized in patients.
Improving Food Allergy Testing & Collaboration
What other specialties should become more involved in the network of care for allergic patients?
Hugh Windom, MD: Understanding Food Allergy Rates
Is the US population having allergies diagnosed correctly, and are allergies on the rise?
FDA Accepts Baloxavir Marboxil sNDA for Flu Complications
The Genentech therapy is currently the first and only single-dose oral medicine marketed for flu treatment, and was the first new flu medicine with a novel mechanism of action in 2 decades.
FDA Approves Esketamine Nasal Spray for Treatment-Resistant Depression
The therapy becomes the first novel mechanism of action-driven drug approved for depression in 30 years.
FDA Commissioner Scott Gottlieb, MD, Resigns
The 23rd FDA commissioner's tenure lasted less than 2 years, since May 2017.
Lidose-Isotretinoin Sustains Long-Term Acne Benefit Without Food Intake
A new, long-term assessment of phase 4 data shows a twice-daily regimen of the common acne therapy can retain patient benefits weeks after treatment ends.
Tildrakizumab Improves Psoriasis Patient Quality of Life
Results from the reSURFACE 1 phase 3 trial shows the biologic is beneficial to patient rates of anxiety, pain, and depression.
Ixekizumab Sustains Plaque Psoriasis Severity Improvement Over 1 Year
Investigators assessed patients’ scores for body surface area, static Physician Global Assessments, and Dermatology QoL Index at 1 month post-index, and at three-month intervals both pre- and post-index.
Study: Tildrakizumab Among Most Cost-Effective Plaque Psoriasis Therapies
New data from AAD show the recently-approved biologic is among the most cost-saving therapies in year 2 of treatment, and beyond.
Dupilumab Improves Atopic Dermatitis Patient Quality of Life
Investigators sought to evaluate the efficacy, safety, psychosocial impact, quality of life, adherence to and satisfaction with the treatment of dupilumab and add-on treatment.
FDA Approves Methylphenidate Hydrochloride for Adult, Pediatric ADHD
The CNS stimulant was approved as an extended-released capsule intended to serve as a first-line ADHD therapy.
Addressing Adult Patients, Comorbidities in Food Allergies
Pediatric peanut allergy trials have proven successful. Now where do researchers look next?
Hugh Windom, MD: Treating Food Allergy with Allergen Exposure
What does the typical patient have to treat aside from their allergy, and what are their treatment goals?
Sanofi Insulin Glargine and Lixsenatide Injection Label Expanded by FDA
The 100 Units/mL/ 300 mcg/mL-dosed therapy was previously approved as an add-on therapy to diet and exercise in adults with T2D.
ACG Releases New Ulcerative Colitis Guideline
The new guideline centers on the overall diagnosis, management, and clinical treatment of the chronic inflammatory disease.
FDA Approves Self-Injection Guselkumab for Plaque Psoriasis
The therapy has been approved for use along with the One-Press injector—a device designed to fit comfortably in the patient’s hand and hide the needle through administration.
Brian Vickery, MD: Food Allergy Guidelines' Role in New Therapies
Have current guidelines been fitted to consider the future of immunotherapy research?
Can Food Challenges Help Individualize Allergy Therapy?
UNC investigators consider the role current food allergy trials may play in addressing gaps of knowledge on patient individualization.
FDA Approves Liquid Colchicine Formulation for Gout
The first liquid formulation of the common gout therapy is anticipated to improve instances of dosing adjustment for patients.
FDA Expands Drug-Eluding Stent to Treat De Novo CTO
The Medtronic platforms were shown in clinical trials to reduce repeat revascularization, cardiac death, and stent thrombosis in 1 year following procedure.
FDA Approves Ophthalmic Gel for Postoperative Inflammation & Pain
The loteprednol etabonate ophthalmic gel 0.38% was proven efficacious and safe in a pair of double-masked trials, and will reach the market by April 2019.
Brian Vickery, MD: Setting Dosing Standards for Immunotherapy Trials
Why it may be critical to reassess dosing practices being practiced in investigative food allergy therapies.
AR-101 and Viaskin Peanut: What's Next in Research?
Kim and Commins discuss what the next series of data on the investigative peanut immunotherapies may mean for the field.
Dupilumab Reduces Type 2 Biomarker Levels in Post Hoc Analysis
The therapy was further assessed in asthmatic patients with comorbid chronic rhinosinusitis and with or without nasal polyposis.
The Biggest Takeaway from AAAAI 2019
UNC School of Medicine colleagues Edwin Kim, MD, MS, and Scott Commins, MD, PhD, explain how the discussion around food allergy care has progressed this year.
David Stukus, MD: Advancing Food Allergy Care
How do current peanut allergy immunotherapies compare, and what other allergens may be addressed next?
Joseph Han, MD: SINUS-24 Trial Results
How did dupilumab fare in patients with chronic rhinosinusitis with nasal polyps?